Roche Diagnostics collaborates with KINDSTAR GLOBAL to promote the establishment of a standardized system for precise diagnosis and treatment of lymphoma diseases in China

Zhitong Finance APP learned that on November 6th, at the 7th China International Import Expo (hereinafter referred to as "CIIE"), Roche Diagnostics Products (Shanghai) Co., Ltd. (hereinafter referred to as "Roche Diagnostics") and KINDSTAR GLOBAL (Wuhan) Medical Special Inspection Technology Co., Ltd. (hereinafter referred to as "KINDSTAR GLOBAL") confirmed their cooperation "to build a standardized system for precise diagnosis and treatment of lymphoma diseases in China" and signed a memorandum of cooperation. Scene of the memorandum signing (Front row: CFO of KINDSTAR GLOBAL, Chai Haijie; Sales Director of Roche Diagnostics China Life Sciences Department, Huang Beibei; Back row: Founder and CEO of KINDSTAR GLOBAL, Huang Shi'ang; Senior Director of Roche Diagnostics China, Wang Feng) The precise diagnosis and treatment market for lymphoma has made significant progress in recent years. With the rapid development of medical technology and a deeper understanding of disease mechanisms, traditional chemotherapy is gradually being replaced by precise targeted and immunotherapy. The demand for precise diagnostic technologies, especially improvements in pathological diagnosis and molecular testing, has made lymphoma diagnosis more accurate. The 5th edition of the classification of hematologic malignancies published by the World Health Organization (WHO) in 2022 requires that pathological diagnosis rely on NGS (next-generation sequencing technology) or other new molecular indicators, reflecting the importance of precise diagnosis. In the process of building a standardized system for precise diagnosis and treatment of lymphoma diseases in China, KINDSTAR GLOBAL has completed testing of over 20,000 clinical samples, leveraging its years of experience in developing molecular diagnostic products for lymphatic system diseases. The mutation profiles tested are consistent with databases and literature, receiving unanimous praise from the clinical community. Recently, KINDSTAR GLOBAL, along with Roche Diagnostics and Roche Pharmaceuticals, will jointly build an integrated ecological circle for lymphoma diagnosis and treatment, aiming to enhance the standardization, precision, and accessibility of lymphoma diagnosis, thereby improving the cure rate for lymphoma patients. All parties will fully utilize each other's resources and advantages to explore and carry out possible clinical research or scientific cooperation in the field of lymphoma, particularly in the construction of "detection standard systems," "expert consensus," and "clinical value" in the lymphoma diagnosis and treatment process. Professor Huang Shi'ang, Founder and CEO of KINDSTAR GLOBAL, stated: "Accurate diagnosis is not only a prerequisite for formulating effective treatment plans but also a key to monitoring disease changes and evaluating treatment effects. Only by ensuring the advancement, popularity, and standardization of diagnostic solutions can we benefit more patients." KINDSTAR GLOBAL has long been committed to the diagnostic monitoring of blood diseases, providing professional blood special testing services. We are very pleased to establish a partnership with Roche Diagnostics to jointly promote the standardization and normalization of NGS systems, contributing more to the improvement of diagnosis and treatment levels for blood diseases.” Mr. Yao Guoliang, General Manager of Roche Diagnostics China, stated: “At the seventh China International Import Expo, we continue to expand our local ecosystem with the 'wind of the Expo', practicing Roche Diagnostics' firm commitment of 'in China, for China' with an open and cooperative spirit, jointly building an integrated diagnosis and treatment system. In the future, we will continue to break through innovations and look forward to working with industry peers to continuously enhance the accessibility and efficient application of high medical value and high-quality diagnostic solutions, accelerate the transformation of scientific research achievements, break the bottleneck in the diagnosis and treatment of blood diseases, achieve the ideal vision of complete cure, and bring blessings to more Chinese patients.”